News & Press Releases

May 12, 2025

Andelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after Diagnosis Andelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after Diagnosis

Press Release

May 6, 2025

Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.

Press Release

February 18, 2025

Andelyn Biosciences Expands AAV Curator® Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and Harvard Andelyn Biosciences Expands AAV Curator® Platform Offering to Include Stanton Lab CNS Capsids through a License Agreement from the Broad Institute of MIT and Harvard

Press Release

October 9, 2024

Andelyn Biosciences Selected by Hubble Therapeutics to Manufacture Clinical Grade AAV for the Treatment of Leber Congenital Amaurosis (LCA16) Andelyn Biosciences Selected by Hubble Therapeutics to Manufacture Clinical Grade AAV for the Treatment of Leber Congenital Amaurosis (LCA16)

Press Release

August 6, 2024

Andelyn Biosciences Expands AAV Curator® Platform Offering to Include MyoAAV Plasmids through a License Agreement from the Broad Institute of MIT and Harvard Andelyn Biosciences Expands AAV Curator® Platform Offering to Include MyoAAV Plasmids through a License Agreement from the Broad Institute of MIT and Harvard

Press Release

July 10, 2024

Andelyn Biosciences Selected by UMass Chan Medical School to Manufacture Clinical Grade AAV9-CSA Vector to Treat Cockayne Syndrome Andelyn Biosciences Selected by UMass Chan Medical School to Manufacture Clinical Grade AAV9-CSA Vector to Treat Cockayne Syndrome

News

June 11, 2024

UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome

Press Release

May 23, 2024

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC)Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC)

Press Release

March 25, 2024

Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency

Press Release

February 28, 2024

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)